Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

Blood

Volumn 125, Issue 5, 2015, Pages 775-783

  De Latour, Régis Peffault ^a,b   Fremeaux Bacchi, Véronique ^c,d   Porcher, Raphaël ^e,f   Xhaard, Aliénor ^a   Rosain, Jérémie ^c,d   Castaneda, Diana Cadena ^c   Vieira Martins, Paula ^c,d   Roncelin, Stéphane ^c   Rodriguez Otero, Paula ^a   Plessier, Aurélie ^g   De Fontbrune, Flore Sicre ^a   Abbes, Sarah ^a   Robin, Marie ^a   Socié, Gérard ^a,h,i  

^a SAINT LOUIS HOSPITAL   (France)

^b Equipe d'Accueil 3518   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔTEL DIEU   (France)

^f PARIS DESCARTES UNIVERSITY   (France)

^g BEAUJON HOSPITAL   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ Institut National de la Sante   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT HEMOLYSIS TEST; COMPLEMENT INHIBITION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; INTRAVASCULAR HEMOLYSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; OUTCOME ASSESSMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTE COUNT; SHEEP ERYTHROCYTE; THROMBOCYTE TRANSFUSION; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLEMENT ACTIVATION; DRUG EFFECTS; DRUG MONITORING; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; IMMUNOASSAY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BILIRUBIN; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; COMPLEMENT C5; DRUG MONITORING; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; IMMUNOASSAY; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED;

EID: 84921786232     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-560540     Document Type: Article

References (36)

1. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell.. 1993;73(4):703-711.
2. Kinoshita T, Ohishi K, Takeda J. GPI-anchor synthesis in mammalian cells: genes, their products, and a deficiency. J Biochem. 1997; 122(2):251-257.
3. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82(4):1192-1196.
4. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17-18):1389-1401.
5. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004; 350(6):552-559.
6. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355(12):1233-1243.
7. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840-1847.
8. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12): 4123-4128.
9. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25): 6786-6792.
10. Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol. 2011;153(6):709-720.
11. DeZern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2013;90(1):16-24.
12. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094-4100.
13. Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95(4):567-573.
14. Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE Jr. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood. 1981;57(1): 83-89.
15. Hartmann RC, Jenkins DE Jr, McKee LC, Heyssel RM. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron. Medicine (Baltimore). 1966;45(5):331-363.
16. Hillmen P, Muus P, Röth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1): 62-73.
17. Kabat EA, Mayer MM. Experimental Immunochemistry, 2nd ed., vol. 4. Springfield, IL: Thomas. 1961.
18. Twisk J, Rijmen F. Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects. J Clin Epidemiol. 2009; 62(9):953-958.
19. Thomas A, O'Hara B, Ligges U, Sturtz S. Making BUGS open. R News. 2006;6(1):12-17.
20. Team RDCR. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. 2011.
21. Rameix-Welti MA, Régnier CH, Bienaimé F, et al. Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. Eur J Immunol. 2007;37(5):1377-1385.
22. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9(11):2644-2645.
23. Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7): 632-639.
24. Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6(6):1488-1494.
25. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(8):1325-1329.
26. Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149(3):446-450.
27. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5): 859-867.
28. Kvarnström AL, Sarbinowski RT, Bengtson JP, Jacobsson LM, Bengtsson AL. Complement activation and interleukin response in major abdominal surgery. Scand J Immunol. 2012;75(5): 510-516.
29. Neher MD, Weckbach S, Flierl MA, Huber-Lang MS, Stahel PF. Molecular mechanisms of inflammation and tissue injury after major trauma - is complement the "bad guy"? J Biomed Sci. 2011;18:90.
30. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014; 124(11):1715-1726.
31. Ferreira VP, Pangburn MK. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood. 2007; 110(6):2190-2192.
32. Ermini L, Goodship TH, Strain L, et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol. 2012;49(4):640-648.
33. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet. 2013;45(7):813-817.
34. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA. 1979; 76(11):5867-5871.
35. Tomita A, Parker CJ. Aberrant regulation of complement by the erythrocytes of hereditary erythroblastic multinuclearity with a positive acidified serum lysis test (HEMPAS). Blood. 1994; 83(1):250-259.
36. Rondelli T, Risitano AM, Peffault de Latour R, et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2014;99(2):262-266.